

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. Which of the following outcomes best describes the progression-free survival (PFS) with trastuzumab deruxtecan (T-DXd) compared to treatment of physician's choice for patients with pretreated HER2-low advanced breast cancer in the DESTINY-BREAST04 study?**
 - Improvement with T-DXd for only those patients with HR-positive disease
 - Improvement with T-DXd for all patients
 - Similar PFS on both study arms
- 2. Which of the following statements best describes the severity of interstitial lung disease (ILD)/pneumonitis observed in patients receiving T-DXd in the DESTINY-BREAST04 trial?**
 - Most events were Grade 1 or 2
 - Most events were Grade 3 or 4
 - All events were Grade 3 or 4
 - ILD was not observed in this population
- 3. What is the frequency of HER2-low tumors among patients with breast cancer?**
 - <1%
 - 8% to 12%
 - 45% to 55%
 - >70%
- 4. Which of the following outcomes best describes PFS observations in the Phase III DESTINY-Breast03 study comparing T-DXd to trastuzumab emtansine (T-DM1) for patients with HER2-positive, unresectable and/or metastatic breast cancer after previous treatment with trastuzumab and a taxane?**
 - PFS was similar with both agents
 - Improvement with T-DM1
 - Improvement with T-DXd
- 5. Which of the following drug types best describes the mechanism of action of the cytotoxic payload of T-DXd?**
 - Tubulin inhibitor
 - Topoisomerase inhibitor
 - DNA damaging agent